S&P 500   5,137.08 (+0.80%)
DOW   39,087.38 (+0.23%)
QQQ   445.61 (+1.51%)
AAPL   179.66 (-0.60%)
MSFT   415.50 (+0.45%)
META   502.30 (+2.48%)
GOOGL   137.14 (-0.95%)
AMZN   178.22 (+0.83%)
TSLA   202.64 (+0.38%)
NVDA   822.79 (+4.00%)
NIO   5.77 (+0.35%)
AMD   202.64 (+5.25%)
BABA   74.63 (+0.81%)
T   17.00 (+0.41%)
F   12.45 (+0.08%)
MU   95.15 (+5.01%)
CGC   3.21 (-2.43%)
GE   158.67 (+1.13%)
DIS   111.93 (+0.31%)
AMC   4.36 (+0.93%)
PFE   26.58 (+0.08%)
PYPL   60.54 (+0.33%)
XOM   105.78 (+1.21%)
S&P 500   5,137.08 (+0.80%)
DOW   39,087.38 (+0.23%)
QQQ   445.61 (+1.51%)
AAPL   179.66 (-0.60%)
MSFT   415.50 (+0.45%)
META   502.30 (+2.48%)
GOOGL   137.14 (-0.95%)
AMZN   178.22 (+0.83%)
TSLA   202.64 (+0.38%)
NVDA   822.79 (+4.00%)
NIO   5.77 (+0.35%)
AMD   202.64 (+5.25%)
BABA   74.63 (+0.81%)
T   17.00 (+0.41%)
F   12.45 (+0.08%)
MU   95.15 (+5.01%)
CGC   3.21 (-2.43%)
GE   158.67 (+1.13%)
DIS   111.93 (+0.31%)
AMC   4.36 (+0.93%)
PFE   26.58 (+0.08%)
PYPL   60.54 (+0.33%)
XOM   105.78 (+1.21%)
S&P 500   5,137.08 (+0.80%)
DOW   39,087.38 (+0.23%)
QQQ   445.61 (+1.51%)
AAPL   179.66 (-0.60%)
MSFT   415.50 (+0.45%)
META   502.30 (+2.48%)
GOOGL   137.14 (-0.95%)
AMZN   178.22 (+0.83%)
TSLA   202.64 (+0.38%)
NVDA   822.79 (+4.00%)
NIO   5.77 (+0.35%)
AMD   202.64 (+5.25%)
BABA   74.63 (+0.81%)
T   17.00 (+0.41%)
F   12.45 (+0.08%)
MU   95.15 (+5.01%)
CGC   3.21 (-2.43%)
GE   158.67 (+1.13%)
DIS   111.93 (+0.31%)
AMC   4.36 (+0.93%)
PFE   26.58 (+0.08%)
PYPL   60.54 (+0.33%)
XOM   105.78 (+1.21%)
S&P 500   5,137.08 (+0.80%)
DOW   39,087.38 (+0.23%)
QQQ   445.61 (+1.51%)
AAPL   179.66 (-0.60%)
MSFT   415.50 (+0.45%)
META   502.30 (+2.48%)
GOOGL   137.14 (-0.95%)
AMZN   178.22 (+0.83%)
TSLA   202.64 (+0.38%)
NVDA   822.79 (+4.00%)
NIO   5.77 (+0.35%)
AMD   202.64 (+5.25%)
BABA   74.63 (+0.81%)
T   17.00 (+0.41%)
F   12.45 (+0.08%)
MU   95.15 (+5.01%)
CGC   3.21 (-2.43%)
GE   158.67 (+1.13%)
DIS   111.93 (+0.31%)
AMC   4.36 (+0.93%)
PFE   26.58 (+0.08%)
PYPL   60.54 (+0.33%)
XOM   105.78 (+1.21%)

United Therapeutics (UTHR) Competitors

$231.92
+6.28 (+2.78%)
(As of 03/1/2024 ET)

UTHR vs. IONS, BBIO, ALKS, MDGL, BMRN, FOLD, ALNY, CTLT, ROIV, and KRTX

Should you be buying United Therapeutics stock or one of its competitors? The main competitors of United Therapeutics include Ionis Pharmaceuticals (IONS), BridgeBio Pharma (BBIO), Alkermes (ALKS), Madrigal Pharmaceuticals (MDGL), BioMarin Pharmaceutical (BMRN), Amicus Therapeutics (FOLD), Alnylam Pharmaceuticals (ALNY), Catalent (CTLT), Roivant Sciences (ROIV), and Karuna Therapeutics (KRTX). These companies are all part of the "medical" sector.

United Therapeutics vs.

Ionis Pharmaceuticals (NASDAQ:IONS) and United Therapeutics (NASDAQ:UTHR) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, valuation, dividends, media sentiment, profitability, analyst recommendations, community ranking, institutional ownership and risk.

Ionis Pharmaceuticals received 111 more outperform votes than United Therapeutics when rated by MarketBeat users. However, 61.40% of users gave United Therapeutics an outperform vote while only 59.91% of users gave Ionis Pharmaceuticals an outperform vote.

CompanyUnderperformOutperform
Ionis PharmaceuticalsOutperform Votes
671
59.91%
Underperform Votes
449
40.09%
United TherapeuticsOutperform Votes
560
61.40%
Underperform Votes
352
38.60%

Ionis Pharmaceuticals has a beta of 0.46, indicating that its stock price is 54% less volatile than the S&P 500. Comparatively, United Therapeutics has a beta of 0.52, indicating that its stock price is 48% less volatile than the S&P 500.

In the previous week, United Therapeutics had 12 more articles in the media than Ionis Pharmaceuticals. MarketBeat recorded 25 mentions for United Therapeutics and 13 mentions for Ionis Pharmaceuticals. Ionis Pharmaceuticals' average media sentiment score of 1.14 beat United Therapeutics' score of 0.44 indicating that United Therapeutics is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Ionis Pharmaceuticals
3 Very Positive mention(s)
2 Positive mention(s)
4 Neutral mention(s)
0 Negative mention(s)
1 Very Negative mention(s)
Neutral
United Therapeutics
10 Very Positive mention(s)
1 Positive mention(s)
3 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

93.9% of Ionis Pharmaceuticals shares are held by institutional investors. Comparatively, 94.1% of United Therapeutics shares are held by institutional investors. 2.7% of Ionis Pharmaceuticals shares are held by insiders. Comparatively, 12.5% of United Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

United Therapeutics has higher revenue and earnings than Ionis Pharmaceuticals. Ionis Pharmaceuticals is trading at a lower price-to-earnings ratio than United Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Ionis Pharmaceuticals$788M8.47-$366.29M-$2.56-17.89
United Therapeutics$2.33B4.74$984.80M$19.8411.81

United Therapeutics has a net margin of 42.31% compared to United Therapeutics' net margin of -46.32%. Ionis Pharmaceuticals' return on equity of 17.72% beat United Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Ionis Pharmaceuticals-46.32% -90.29% -12.39%
United Therapeutics 42.31%17.72%14.47%

Ionis Pharmaceuticals presently has a consensus target price of $53.23, indicating a potential upside of 16.79%. United Therapeutics has a consensus target price of $292.80, indicating a potential upside of 29.76%. Given Ionis Pharmaceuticals' stronger consensus rating and higher possible upside, analysts clearly believe United Therapeutics is more favorable than Ionis Pharmaceuticals.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Ionis Pharmaceuticals
2 Sell rating(s)
3 Hold rating(s)
7 Buy rating(s)
1 Strong Buy rating(s)
2.54
United Therapeutics
0 Sell rating(s)
1 Hold rating(s)
10 Buy rating(s)
0 Strong Buy rating(s)
2.91

Summary

United Therapeutics beats Ionis Pharmaceuticals on 16 of the 19 factors compared between the two stocks.


Get United Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for UTHR and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding UTHR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

UTHR vs. The Competition

MetricUnited TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ Exchange
Market Cap$11.03B$6.76B$4.98B$7.56B
Dividend YieldN/A2.82%2.87%3.87%
P/E Ratio11.8110.01198.2614.62
Price / Sales4.74225.483,058.9375.64
Price / Cash10.2919.1096.0754.95
Price / Book1.844.874.554.70
Net Income$984.80M$158.07M$114.14M$211.39M
7 Day Performance3.24%7.17%5.28%3.03%
1 Month Performance8.53%13.96%9.81%5.85%
1 Year Performance-4.29%7.82%13.45%9.15%

United Therapeutics Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
IONS
Ionis Pharmaceuticals
3.7268 of 5 stars
$47.41
+2.8%
$53.23
+12.3%
+25.9%$6.91B$788M-18.52796Short Interest ↑
BBIO
BridgeBio Pharma
4.4392 of 5 stars
$35.73
+2.5%
$42.29
+18.3%
+199.0%$6.28B$9.30M-9.07550Analyst Revision
ALKS
Alkermes
2.7712 of 5 stars
$29.70
-1.1%
$32.50
+9.4%
+11.0%$4.96B$1.66B14.352,100Positive News
MDGL
Madrigal Pharmaceuticals
4.0156 of 5 stars
$239.80
+3.1%
$294.14
+22.7%
-12.8%$4.73BN/A-12.4692Earnings Report
Analyst Report
Analyst Revision
News Coverage
BMRN
BioMarin Pharmaceutical
4.8225 of 5 stars
$90.68
+0.6%
$109.74
+21.0%
-13.4%$17.08B$2.42B103.053,082Analyst Report
Analyst Revision
FOLD
Amicus Therapeutics
4.1282 of 5 stars
$13.85
+0.5%
$17.20
+24.2%
-2.8%$4.06B$329.23M-23.47484Analyst Report
Short Interest ↑
News Coverage
ALNY
Alnylam Pharmaceuticals
4.7226 of 5 stars
$159.00
+0.2%
$216.12
+35.9%
-21.1%$20.03B$1.83B-44.662,100
CTLT
Catalent
3.5845 of 5 stars
$58.24
-0.1%
$52.46
-9.9%
-15.9%$10.53B$4.28B-8.5617,800Short Interest ↓
ROIV
Roivant Sciences
3.9745 of 5 stars
$11.80
+0.9%
$16.50
+39.8%
+41.4%$9.51B$61.28M2.27904Positive News
KRTX
Karuna Therapeutics
0.8756 of 5 stars
$314.89
-0.3%
$293.92
-6.7%
+57.4%$12.01B$654,000.00-26.87210Short Interest ↑

Related Companies and Tools

This page (NASDAQ:UTHR) was last updated on 3/1/2024 by MarketBeat.com Staff